View in EDS HTML Full Text PDF Full Text

Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.

Saved in:
Bibliographic Details
Title: Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.
Authors: Patti, Francesco (AUTHOR), Chisari, Clara Grazia (AUTHOR), Solaro, Claudio (AUTHOR), Benedetti, Maria Donata (AUTHOR), Berra, Eliana (AUTHOR), Bianco, Assunta (AUTHOR), Bruno Bossio, Roberto (AUTHOR), Buttari, Fabio (AUTHOR), Castelli, Letizia (AUTHOR), Cavalla, Paola (AUTHOR), Cerqua, Raffaella (AUTHOR), Costantino, Gianfranco (AUTHOR), Gasperini, Claudio (AUTHOR), Guareschi, Angelica (AUTHOR), Ippolito, Domenico (AUTHOR), Lanzillo, Roberta (AUTHOR), Maniscalco, Giorgia Teresa (AUTHOR), Matta, Manuela (AUTHOR), Paolicelli, Damiano (AUTHOR), Petrucci, Loredana (AUTHOR)
Source: Neurological Sciences. Oct2020, Vol. 41 Issue 10, p2905-2913. 9p. 1 Diagram, 2 Charts, 2 Graphs.
Subjects: Spasticity, Cannabidiol, Symptoms, Multiple sclerosis, Medication therapy management, Spraying, Research, Combination drug therapy, Research methodology, Retrospective studies, Medical cooperation, Evaluation research, Hydrocarbons, Comparative studies, Plant extracts, Disease complications
Geographic Terms: Italy
Abstract: Introduction: The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex®) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity. We aimed to investigate the improvement of MS spasticity-related symptoms in a large cohort of patients with moderate to severe spasticity in daily clinical practice.Materials and Methods: MS patients with drug-resistant spasticity were recruited from 30 Italian MS centers. All patients were eligible for THC:CBD treatment according to the approved label: ≥ 18 years of age, at least moderate spasticity (MS spasticity numerical rating scale [NRS] score ≥ 4) and not responding to the common antispastic drugs. Patients were evaluated at baseline (T0) and after 4 weeks of treatment (T1) with the spasticity NRS scale and were also asked about meaningful improvements in 6 key spasticity-related symptoms.Results: Out of 1615 enrolled patients, 1432 reached the end of the first month trial period (T1). Of these, 1010 patients (70.5%) reached a ≥ 20% NRS score reduction compared with baseline (initial responders; IR). We found that 627 (43.8% of 1432) patients showed an improvement in at least one spasticity-related symptom (SRSr group), 543 (86.6%) of them belonging to the IR group and 84 (13.4%) to the spasticity NRS non-responders group.Conclusion: Our study confirmed that the therapeutic benefit of cannabinoids may extend beyond spasticity, improving spasticity-related symptoms even in non-NRS responder patients. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
Description
Abstract:<bold>Introduction: </bold>The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex®) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity. We aimed to investigate the improvement of MS spasticity-related symptoms in a large cohort of patients with moderate to severe spasticity in daily clinical practice.<bold>Materials and Methods: </bold>MS patients with drug-resistant spasticity were recruited from 30 Italian MS centers. All patients were eligible for THC:CBD treatment according to the approved label: ≥ 18 years of age, at least moderate spasticity (MS spasticity numerical rating scale [NRS] score ≥ 4) and not responding to the common antispastic drugs. Patients were evaluated at baseline (T0) and after 4 weeks of treatment (T1) with the spasticity NRS scale and were also asked about meaningful improvements in 6 key spasticity-related symptoms.<bold>Results: </bold>Out of 1615 enrolled patients, 1432 reached the end of the first month trial period (T1). Of these, 1010 patients (70.5%) reached a ≥ 20% NRS score reduction compared with baseline (initial responders; IR). We found that 627 (43.8% of 1432) patients showed an improvement in at least one spasticity-related symptom (SRSr group), 543 (86.6%) of them belonging to the IR group and 84 (13.4%) to the spasticity NRS non-responders group.<bold>Conclusion: </bold>Our study confirmed that the therapeutic benefit of cannabinoids may extend beyond spasticity, improving spasticity-related symptoms even in non-NRS responder patients. [ABSTRACT FROM AUTHOR]
ISSN:15901874
DOI:10.1007/s10072-020-04413-6